These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 9566048

  • 21. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
    Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JA, Berecz R, Duran M, Benítez J.
    J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
    [Abstract] [Full Text] [Related]

  • 22. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
    Dorado P, Peñas-LLedó EM, de la Rubia A, LLerena A.
    Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
    [Abstract] [Full Text] [Related]

  • 23. Blood levels of neuroleptics: state of the art.
    Simpson GM, Yadalam K.
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):22-8. PubMed ID: 2859277
    [Abstract] [Full Text] [Related]

  • 24. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine.
    Wójcikowski J, Maurel P, Daniel WA.
    Drug Metab Dispos; 2006 Mar; 34(3):471-6. PubMed ID: 16272405
    [Abstract] [Full Text] [Related]

  • 25. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
    Rao ML, Brown WA, Wagner R.
    Ther Drug Monit; 1988 Mar; 10(2):184-7. PubMed ID: 3381236
    [Abstract] [Full Text] [Related]

  • 26. S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteers.
    Chakraborty BS, Hawes EM, McKay G, Hubbard JW, Korchinski ED, Midha KK, Choc MG, Robinson WT.
    Drug Metabol Drug Interact; 1988 Mar; 6(3-4):425-37. PubMed ID: 3271648
    [Abstract] [Full Text] [Related]

  • 27. Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat.
    Lin G, Hawes EM, McKay G, Korchinski ED, Midha KK.
    Xenobiotica; 1993 Oct; 23(10):1059-74. PubMed ID: 8259689
    [Abstract] [Full Text] [Related]

  • 28. Thioridazine-fluoxetine interaction at the level of the distribution process in vivo.
    Wójcikowski J, Daniel WA.
    Pol J Pharmacol; 2002 Oct; 54(6):647-54. PubMed ID: 12866720
    [Abstract] [Full Text] [Related]

  • 29. Effects of selective cytochrome P-450 inhibitors on the metabolism of thioridazine. In vitro studies.
    Daniel WA, Syrek M, Haduch A.
    Pol J Pharmacol; 1999 Oct; 51(5):435-42. PubMed ID: 10817545
    [Abstract] [Full Text] [Related]

  • 30. Concentration and distribution of thioridazine and metabolites in schizophrenic post-mortem brain tissue.
    Svendsen CN, Hrbek CC, Casendino M, Nichols RD, Bird ED.
    Psychiatry Res; 1988 Jan; 23(1):1-10. PubMed ID: 3363012
    [Abstract] [Full Text] [Related]

  • 31. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
    Aravagiri M, Marder SR.
    Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
    [Abstract] [Full Text] [Related]

  • 32. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
    LLerena A, Berecz R, de la Rubia A, Dorado P.
    J Psychopharmacol; 2002 Dec; 16(4):361-4. PubMed ID: 12503836
    [Abstract] [Full Text] [Related]

  • 33. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma.
    Eap CB, Koeb L, Powell K, Baumann P.
    J Chromatogr B Biomed Appl; 1995 Jul 21; 669(2):271-9. PubMed ID: 7581903
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats.
    Tasso L, Neves G, Menegatti R, Fraga CA, Barreiro E, Eifler-Lima V, Rates SM, Costa TD.
    Eur J Pharm Sci; 2005 Oct 21; 26(2):194-202. PubMed ID: 16076552
    [Abstract] [Full Text] [Related]

  • 35. Distribution interactions between perazine and antidepressant drugs. In vivo studies.
    Wójcikowski J, Daniel WA.
    Pol J Pharmacol; 2000 Oct 21; 52(6):449-57. PubMed ID: 11334238
    [Abstract] [Full Text] [Related]

  • 36. Metabolism of thioridazine in the elderly.
    Cohen BM, Sommer BR.
    J Clin Psychopharmacol; 1988 Oct 21; 8(5):336-9. PubMed ID: 3183071
    [Abstract] [Full Text] [Related]

  • 37. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
    Llerena A, Berecz R, de la Rubia A, Norberto MJ, Benítez J.
    Ther Drug Monit; 2000 Aug 21; 22(4):397-401. PubMed ID: 10942178
    [Abstract] [Full Text] [Related]

  • 38. Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats.
    Kastner M, Rahm U, Baumann-Wilschke I, Bello A, Stahlmann R.
    Arch Toxicol; 2004 Feb 21; 78(2):61-7. PubMed ID: 14661070
    [Abstract] [Full Text] [Related]

  • 39. Partitioning of thioridazine and mesoridazine in human blood fractions.
    Dinovo EC, Pollak H, Gottschalk LA.
    Methods Find Exp Clin Pharmacol; 1984 Mar 21; 6(3):143-6. PubMed ID: 6748818
    [Abstract] [Full Text] [Related]

  • 40. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.
    Cohen BM, Lipinski JF, Waternaux C.
    Psychopharmacology (Berl); 1989 Mar 21; 97(4):481-8. PubMed ID: 2498945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.